Healthy
Conditions
Brief summary
The purpose of this study is to evaluate the tolerability, safety and pharmacokinetics of PF-06650833 orally administered as modified release tablets in healthy Japanese subjects.
Interventions
DRUGPF-06650833
DRUGplacebo
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy female subjects of non childbearing potential and/or male Japanese subjects between the ages of 20 and 55 years, inclusive. 2. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). 3. Subject must have four Japanese grandparents who were born in Japan. 4. Evidence of a personally signed and dated informed consent document. 5. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion criteria
1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. 2. Any condition possibly affecting drug absorption (eg, gastrectomy). 3. A positive urine drug screen. 4. Smoking cigarettes with exceeding provided criteria. 5. History of regular alcohol consumption exceeding provided limitations. 6. Treatment with an investigational drug within a provided criteria. 7. Abnormal supine blood pressure. 8. Abnormal pulse rate. 9. Abnormal 12 lead ECG. 10. History of tuberculosis. 11. History of hepatitis or positive testing for HIV, hepatitis B surface antigen, hepatitis B surface antibodies, hepatitis B core antibodies, hepatitis C antibodies or syphilis. 12. Any medical history of disease (ie, Gilbert's disease). 13. Abnormal clinical laboratory test related to cardiac and skeletal muscle injury. 14. Male subjects with partners currently pregnant; unwilling or unable to use a highly effective method of contraception 15. Use of prescription or nonprescription drugs, vitaminic and dietary supplements within a specified duration. 16. Blood donation exceeding a provided limitation. 17. History of sensitivity to heparin or heparin induced thrombocytopenia. 18. History of cancer (other than treated basal cell and squamous cell carcinoma of the skin) in the previous 5 years. 19. Unwilling or unable to comply with the Lifestyle guidelines described in this protocol. 20. Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are Pfizer employees directly involved in the conduct of the study. 21. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants experiencing an AE/SAE | Day 18 |
Secondary
| Measure | Time frame |
|---|---|
| Area under the plasma concentration time curve for dosing interval (AUCtau) | Day 1 and Day 10 |
| Time to peak concentration | Day 1 and Day 10 |
| Clearance | Day 10 |
| Volume of distribution | Day 10 |
| Observed exposure accumulation ratio for AUCtau | Day 10 |
| Observed exposure accumulation ratio for Cmax | Day 10 |
| Maximum plasma concentration (Cmax) | Day 1 and Day 10 |
| Fluctuation ratio (Cmax:Cmin) | Day 10 |
| Mean residence time | Day 10 |
| change from baseline in vital signs | Day 18 |
| change form baseline in electrocardiogram (ECG) parameters | Day 18 |
| Incidence of treatment emergent clinical laboratory abnormalities | Day 18 |
| Minimum plasma concentration (Cmin) | Days 2, 4, 7 and 10 |
Countries
Japan
Outcome results
None listed